Foegh M L, Winchester J F, Zmudka M, Helfrich G B, Cooley C, Ramwell P W, Schreiner G E
Lancet. 1981 Aug 29;2(8244):431-4. doi: 10.1016/s0140-6736(81)90772-8.
Immunoreactive thromboxane B2 (i-TXB2) was measured in daily urine samples from twelve patients after renal transplantation. In 21 of 30 rejection episodes, the increase in i-TXB2 preceded both the increase in serum beta 2-microglobulin (beta 2-MG) and the clinical diagnosis of rejection. In 26 of 30 rejection episodes, the increase in urine i-TXB2 preceded the increase in serum creatinine. The degree of change in i-TXB2 is greater than that of either serum beta 2-MG or creatinine. Urinary i-TXB2 was very high in one patient with deep venous thrombosis, but it did not rise in patients with urinary tract infection, pneumonia, or acute tubular necrosis. Thus, urinary i-TXB2 seems to be an early indicator of clinical renal allograft rejection.
对12例肾移植患者的每日尿样进行免疫反应性血栓素B2（i-TXB2）检测。在30次排斥反应中的21次，i-TXB2升高先于血清β2-微球蛋白（β2-MG）升高及排斥反应的临床诊断。在30次排斥反应中的26次，尿i-TXB2升高先于血清肌酐升高。i-TXB2的变化程度大于血清β2-MG或肌酐。1例深静脉血栓形成患者的尿i-TXB2非常高，但尿路感染、肺炎或急性肾小管坏死患者的尿i-TXB2未升高。因此，尿i-TXB2似乎是临床肾移植排斥反应的早期指标。
